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C s e p r B n  V I I I
During the recent years, increasing knowledge has been obtained regarding patients with
thrombocytopenia with a normal number of megakaryocytes in the bone marrow. Especially
platelet kinetic studies have been helpful to categorise the different subgroups related to
decreased production by bone maÍïow dysfunction or thrombocytopenia due to increased
peripheral destruction.
Chapter III describes the use of two 11lln ligands, rrrln-oxinate and lrrln-tropolonate. First,
a series of in vitro investigations has been performed in order to measure the labelling
efficiency and the viability of autologous platelets labelled with lrlIn-tropolonate compared
to llrln-oxinate. Using lllln tropolonate, it was possible to label autologous platelets in a
plasma environment, thus improving the labelling efficiency to 95Vo as compared to 607o
with lrlln oxinate. In physiological saline no difference was observed: both ligands showed
labetlingefficiencies overg0To. l l l lnl igandsenableautologousplateletlabell ingevenata
platelet count below 25 x l}e /L. Loss in platelet viability could not be demonstrated since
there was no obvious difference in aggregation with adenosine diphosphate (ADP) before
and after platelet labelling, neither with lrrln-tropolonate nor with rrrln-oxinate. Based on
the favourable results with nrln-tropolonate, a complete set of in vivo investigations,
including mean platelet life and organ measurements were performed using tropolonate
only. It was demonstrated that the spleen rapidly took up autologous platelets labelled with
rlrln-tropolonate. In normals the uptake lies within a sharply defined range, and remains
constant for five to seven days. Similar results were obtained from the liver uptake. In
thrombocytopenic patients however, MPL and PPR vary from normal to greatly reduced.
These results indicate that the labelling procedure withrlrln-tropolonate can be used
adequately to perform platelet kinetic studies.
In chapter IV the value of platelet kinetics is described in a 'homogeneous' group of 141
ITP patients. It was to be expected that the majority would present with decreased MPL and
normal to increased compensatory platelet production. Indeed, bone marrow analysis
demonstrated a normal to increased number of megakaryocytes in the majority of cases.
However, no correlation was observed between the morphological findings and PPR
determined with the platelet kinetic studies. Based on these results, patients with ITP can
be divided into two sub-groups. The first group showed the conventional picture of ITP
(short MPL, normal to increased PPR and increased destruction in the spleen). The second
patient group (407o) demonstrated ineffective thrombopoiesis reflected by longer MPL,
and a decreased PPR.
In view of the heterogeneity of the patients groups, the impact of therapy needed to be
evaluated (Chapter V). ITP patients were studied before and during prednisone therapy
(n=17) andbefore and after splenectomy (n=24). In the prednisolone group, it was shown
that patients responsive to therapy demonstrated especially an improvement in PPR, with
minor effects on MPL. All patients with a normal platelet count after prednisolone preserve
a significant shortened MPL.
In contrast, patients responsive to.splenectomy and normalisation of peripheral platelet
count demonstrated especially normalisation of the MPL and PPR in contrast to non-
responsive patients. These facts suggest that although prednisone increases PPR, complete
response seems only possible if, at the same time MPL is prolonged. These findings suggest
that both prednisolone and splenectomy reduce the amount of platelet associated
autoantibodies. However, complete remission occurred only in splenectomized patients.
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In chapter VI a patient selection was made based on reduced PPR in the platelet kinetics, in
order to analyse whether PPR was due to reduced platelet production in the bone marrow,
reflected by increased TPO levels, or due to increased medullary destruction translated into
an elevated GC-Index.
TPO plasma levels were not statistically different from normal controls; neither could
a significant difference between ITP patients with a normal to increased PPR versus patients
with a decreased PPR be demonstrated. In contrast, GC-index in ITP patients with reduced
PPR was significantly higher than in patients with normal to increased PPR. This discrepancy
between a decreased number of platelets released into the circulation and an increased
release of GP-Ib complex suggests hedding of the receptor complex from megakaryocytes
and/or platelets destructed in the bone marrow. However it is not likely that this is associated
with a reduced mass of TPO bearing cells in view of the normal TPO levels. The finding
that no significant correlation existed between GC-index and MPL further supports the
hypothesis of increased medullary destruction. The results indicate that in a sub-group of
ITP patients thrombocytopenia may be caused by increased megakaryocyte- and platelet
destruction in the bone maÍïow.
Finally, chapter VII describes another application of autologous labelled platelets. Platelet
kinetics were performed in eight patients with paroxysmal nocturnal haemoglobinuria (PNH)
in order to define the cause of thrombocytopenia.
The majority of PNH patients had reduced PPR, indicating ineffective thrombopoiesis
since bone marrow examination demonstrated hyper- or normocellular bone marrow. It
was remarkable that virtually all PNH patients showed increased accumulation of platelets
in the abdominal blood vessels, not associated with clinical signs of thrombosis. PNH patients
have an increased tendency to thrombosis especially in abdominal veins. This might be
partly due to increased tendency of platelets to adhere to the endothelial cell layer. The
findings indicate that platelet kinetics have no value for the diagnostic process of thrombosis
in PNH. Alternatives have to be used such as Ultrasound imaging and MRI.
FUTURE PERSPECTIVES FOR THROMBOCYTOPENIA
This thesis demonstrates that contrary to the ASH ITP practice guidelines (Blood 1996; 88:
3-40), ITP cannot be considered a homogeneous disorder, but that it appears to be divided
into different subgroups. Platelet kinetic studies have revealed that two sub-groups ofpatients
can be recognised whereby a significant difference is observed with regard to the release of
platelets in the circulation i.e. the PPR. Platelet kinetic studies and plasma GC and TPO
levels indicate that the reduced PPR in a subgroup of patients is related to an increased
intramedullar destruction of platelets and megakaryocytes. These findings may require
alternative approaches for classification, diagnosis and treatment.
The results described in chapter VI indicate that the GC-I is an important tool to
distinguish these subgroups of ITP patients and it may be of use for further classification of
ITP patients.
In addition, alternative methods may be developed to label platelets. In 1993, trace
labelling of platelets with biotin in whole blood has been described. The in vivo behaviour
and the life span of biotinylated platelets is similar to platelets labelled with radionuclides,
suggesting that this method might be an appropriate substitute in humans also. The label
adheres to all platelet cohot'ts and they can be monitored by flow cytometric techniques, so
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risk effects are minimal. Because of these advantages, this technique may be an ideal
alternative to radionuclidic methods. Possible toxic and immunological effects will have to
be monitored closely before this method can be introduced for widespread human use.
Sofar the determination of platelet associated immunoglobulins does not have important
diagnostic or prognostic value. However, the results in the subgroups of ITP patients suggest
that antibodies are not only directed to platelets but also to megakaryocytes. Moreover
different subtypes of autoantibodies may be present since no difference in MPLwas observed
in patients with a reduced versus normal or increased PPR. Further research will have to
focus on the identification ofthe platelet autoantibodies.
Preliminary results indicate that increased apoptosis ofmegakaryocytes is observed in
patients presenting with ITP. Whether this can be related to patients not responding to
prednisone and splenectomy has to be evaluated. Demonstration of apoptosis of
megakaryocytes in patients with ITP would evidently open up the possibility of new
therapeutic options especially for non-responsive patients. Agents that affect this process
of apoptosis might be of great relevance including agents like the haematopoietic growth
factor TPO that might prove of eminent value for the treatment of patients with ITP.
